Country Information


Rwanda

 
HIV prevalence 15-49, 2007/2008 2.8%
Tuberculosis death rate 102/100,000 population
Malaria death rate (children under 5) 1,049/100,000 population
 
   
             
     
  Rwanda is a small, mountainous, densely populated nation located in central Africa. In the 1990s the country grabbed world headlines as a genocidal civil war between Rwanda's Hutu majority and Tutsi minority ethnic groups left over 900,000 people dead and another four million displaced. The country is currently rebuilding and returning to normalcy.

Though major causes of illness and death in Rwanda have been malaria, respiratory infections, and tuberculosis, AIDS is rapidly becoming the number one killer in the country. UNAIDS estimated at the end of 2001 that HIV/AIDS had infected 8.9 percent of adult Rwandans, and orphaned 260,000 children. The epidemic is expected to reduce Rwandan life expectancy to 32 years by 2010.

Before the political turmoil of the mid-1990s, the infection rate was much higher in urban areas than rural areas, where most of the population lived. But the civil war, by creating huge population movements and refugee camps, changed that pattern so that by 1997 the urban-rural gap in HIV prevalence was closing.

Sources: BBC country profile, Joint United Nations Programme on HIV/AIDS (UNAIDS), Synergy Project

 
           
             
  Rwanda has developed a national strategic plan for 2002-2006 for fighting HIV/AIDS. The full cost of the program is an estimated $68.6 million. The plan is multisectoral and involves the public sector, the private sector, NGOs, civic groups, and religious groups.

Source: Synergy Project

 
           
             
 
Total population. mid-2009 9.9 (millions)
HIV prevalence 15-49, 2007/2008 2.8%
Tuberculosis death rate 102/100,000 population
Prevalence of tuberculosis per 100,000 population, 2000 555
Prevalence of tuberculosis per 100,000 population, 2004 660
% Tuberculosis detection rate under DOTS, 2001 27
% Tuberculosis detection rate under DOTS, 2004 30
% Tuberculosis treatment success rate under DOTS, 2000 62
% Tuberculosis treatment success rate under DOTS, 2003 68
Malaria death rate (children under 5) 1,049/100,000 population
GNI PPP Per Capita, 2008 101 (US$)
Life expectancy at birth 48 years
Infant mortality rate 62/1,000 live births
Total fertility rate 5.5 per woman
Crude birth rate 41/1,000 population
Crude death rate 16/1,000 population
Adult male literacy level 77% (pct. 15+ literate)
Adult female literacy level 76% (pct. 15+ literate)
Contraceptive prevalence rate, modern methods 27% of women in union
Estimated number of people living with HIV: Adults and Children, 2005 190,000
Estimated number of people living with HIV: Adults and children, end 2003 250,000
Estimated number of people living with HIV: Adults and children, end 2001 240,000
Estimated number of people living with HIV: Adults (15+), 2005 160,000
Estimated number of people living with HIV: Adults (15-49), end 2003 230,000
Estimated number of people living with HIV: Adults (15-49), end 2001 220,000
Estimated number of people living with HIV: Adults (15-49) rate (%), 2005 5.1%
Estimated number of people living with HIV: Adults (15-49) rate (%), 2003 5.1%
Estimated number of people living with HIV: Women (15+), 2005 91,000
Estimated number of people living with HIV: Women 15-49, end 2003 130,000
Estimated number of people living with HIV: Women 15-49, end 2001 120,000
Estimated number of people living with HIV: Children (0-14), 2005 27,000
Estimated number of people living with HIV: Children (0-14), end 2003 22,000
Estimated number of people living with HIV: Children (0-14), end 2001 20,000
Estimated number of AIDS deaths: Adults and children, 2005 21,000
AIDS deaths in adults and children, end 2003 22,000
AIDS deaths in adults and children, end 2001 21,000
Estimated number of orphans due to AIDS: Children (0-17), 2005 210,000
Orphans due to AIDS (0-17), living 2003 160,000
Orphans due to AIDS (0-17), living 2001 160,000
% Women (15-49), currently married or living with a partner, who have ever discussed AIDS prevention with their husband or partner 66%

Demographic data contained in this section was obtained from the following sources: The Population Reference Bureau’s 2009 World Population Data Sheet was used for total population, life expectancy at birth, infant mortality, fertility, birth rate, death rate, % of married women 15-49 using modern methods of contraception, % of population 15-49 with HIV/AIDS in 2007/2008, and the GNI PPP per capita (2008). Literacy rates were found in the Population Reference Bureau’s publication 2005 Women of Our World. HIV prevalence data for 2001 and 2003 was obtained from the UNAIDS Barcelona 2002 report; HIV prevalence and orphan data for 2005 was obtained from the UNAIDS Report on the Global AIDS Epidemic 2006. Data on the % women who have discussed AIDS prevention with their husband or partner can be found in ORC Macro and USAID’s Women’s Lives and Experiences: Changes in the Past Ten Years (Research Findings from the Demographic and Health Surveys). Childhood malaria mortality data was accessed in 2003 from the United Nations Statistics Divisions’ Millennium Indicators. Tuberculosis data was obtained from the United Nations Statistics Division’s Millennium Indicators: MDGInfo 2006. In some cases information was unavailable.

 
           
             
  Rwanda has about 30 hospitals, including a referral hospital and 2-3 smaller hospitals in each prefecture. There are also approximately 30 health centers providing primary health care for many Rwandese. Rwanda has approximately one physician for every 60,000 inhabitants.

 
           
             
 

National University of Rwanda, School of Public Health

National University of Rwanda, Faculty of Medicine

Treatment and Research AIDS Center (TRAC)

TRAC is a program of Rwanda's Ministry of Health, and a partner in the MTCT-Plus Initiative which aims to reduce mother-to-child transmission of HIV in a number of high-burden countries.

 
           
             
 

Entity

Project Title

Diseases

Primary Category

Secondary Category

NIH Virologic Correlates of Heterosexual Transmission HIV/AIDS Epidemiology  
  (PI: Eric Hunter. 2002-2007.) A University of Alabama study to identify HIV-1 viruses transmitted between members of HIV-discordant heterosexual...

NIH Couples HIV Counseling and Testing in Two African Capitals HIV/AIDS Prevention  
  (PI: Susan Allen. 2002-2007.) A research team based at the University of Alabama is implementing this voluntary counseling and testing program for...

NIH Ethics Substudy Of An Anti-malarial Efficacy Study Malaria General  
  (PI GRADY, CHRISTINE P 2003) From project abstract: "This substudy seeks to inform deliberation and resolution of ethical issues related to...

Other US USAID HIV/AIDS,Tuberculosis General  
  The USAID program in Rwanda, budgeted at $24.687 million in FY 2002, and with a proposed budget of $29.152 million for FY 2003, is focused on the...

International A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel HIV/AIDS Drug Development Drug Development
  International Partnership for Microbicides, Inc. (Study Director: Zeda Rosenberg; Rwanda PIs: Joseph Vyankandondera, Janneke van de Wijgert)...

International An Expanded Safety Study of Dapivirine Gel 4759 in Africa HIV/AIDS Drug Development Prevention
  International Partnership for Microbicides, Inc.(Study Director: Dr. Annalene Nel). 330 HIV-negative women between the ages of 18 and 40 will be...

International An Expanded Safety Study of Dapivirine Gel 4789 in Africa HIV/AIDS Drug Development Prevention
  International Partnership for Microbicides, Inc.(Study Director: Dr. Annalene Nel). 320 HIV-negative women between the ages of 18 and 40 will be...

International International AIDS Vaccine Initiative (IAVI) HIV/AIDS Drug Development  
  In March 2003 IAVI is expanding human trials of a DNA-MVA vaccine, already in trials in Kenya, to include 45 subjects in Kigali, Rwanda. The vaccine...

International Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children with Falciparum Malaria Malaria Drug Development  
  University Hosptial Ghent, with Centre Hospitalier De Butare. (PIs: Luc Van Bortel, Mark Twagirumukiza). This trial will test the effectiveness...

International IPT of Malaria with SP in Different Zones of Drug Resistance in Rwanda Malaria Prevention  
  Institute of Tropical Medicine, Belgium (Study Director: Umberto D'Alessandro; PI: Daniel Ngamije). This study will examine the impact of an...

International Luxembourg/ESTHER HIV/AIDS General  
  As part of the ESTHER initiative (also including Italy, France and Spain), Luxembourg has pledged $9.6 million (11 million euros) for two three-year...

International Germany HIV/AIDS General  
  In May 2005 Rwanda and Germany signed a Memorandum of Understanding (MoU) worth eight million Euros (about $10.1 million) that will support good...

International Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) HIV/AIDS,Tuberculosis,Malaria General  
  Rwanda has had several grant proposals approved by the GFATM. These include:
  • A Round 1 grant to improve the health system's response to HIV
...

Foundation Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission HIV/AIDS Drug Development Prevention
  (Study Chairs: Connie Celum, Jairam Lingappa, Anna Wald. Rwanda PI: Susan Allen) This study will enrol 3000 couples in Africa in which one...

Foundation MTCT-Plus Initiative HIV/AIDS Prevention  
  The MTCT-Plus Initiative aims to prevent mother-to-child transmission of HIV in Rwanda and several other developing nations with high HIV/AIDS...

Foundation Clinton Foundation HIV/AIDS Initiative HIV/AIDS General  
  The William J. Clinton Presidential Foundation has negotiated with pharmaceutical companies to obtain reduced prices for ARV drugs and HIV/AIDS...

 
           
             
  No information available  
           



Home || HIV/AIDS || Tuberculosis || Malaria || Advanced Search || Links || Contact Us

Last site update: September 03, 2009

For questions, or to report problems with this site, please contact the Webmaster.

Disclaimer